Aldeyra's reproxalap NDA accepted by FDA with April 2, 2025 PDUFA; expands AbbVie option deal

Aldeyra Therapeutics, Inc.

FDA accepted resubmitted NDA for reproxalap for dry eye disease; PDUFA date April 2, 2025.
Expanded option with AbbVie: upon exercise, AbbVie pays $100M upfront (less $6M fees) plus up to $300M milestones.
If option exercised, profit/loss split 60% AbbVie, 40% Aldeyra; Aldeyra pre-commercial costs 60% reimbursed by AbbVie.
Option exercise period amended to 10 business days after FDA approval of reproxalap for dry eye disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.